Business
Aytu BioPharma Reports Fiscal 2026 Third Quarter Operational and Financial Results
EXXUA -- with only a partial quarter of full sales force support -- contributed $2.4 million in net revenue supported by rapid monthly compounding script growth rates Total net revenue of $12.4 million Adjusted EBITDA1 of $(2.8) million, which includes ...
About this update from Aytu Biopharma, Inc.
[{"type":"text","content":"EXXUA -- with only a partial quarter of full sales force support -- contributed $2.4 million in net revenue supported by rapid monthly compounding script growth rates","length":166,"tagName":"p"},{"type":"text","content":"Total net revenue of $12.4 million","length":34,"tagName":"p"},{"type":"text","content":"Adjusted EBITDA1 of $(2.8) million, which includes EXXUA™ (gepirone) extended-release tablets ("EXXUA") launch investments as the Company enters the over $22 billion United States prescription major depressive disorder ("MDD") market","length":263,"tagName":"p"},{"type":"text","content":"$26.7 million cash balance at March 31, 2026","length":44,"tagName":"p"},{"type":"text","content":"Company to host conference call and webcast today, May 13, 2026, at 4:30 p.m. Eastern time","length":90,"tagName":"p"},{"type":"text","content":"DENVER, CO / ACCESS Newswire / May 13, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced operational and financial results for the fiscal 2026 third quarter.","length":368,"tagName":"p"},{"type":"text","content":"Q3 Fiscal 2026 Highlights","length":25,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Net revenue of $12.4 million versus $18.5 million in Q3 fiscal 2025.","length":68,"tagName":"p"}]},{"val":[{"type":"text","content":"EXXUA net revenue was $2.4 million during Q3 fiscal 2026. EXXUA was only made commercially available in mid-December 2025, and more formally launched in mid-January 2026 following the completion of sales force training highlighting strong adoption in the initial weeks of the full launch.","length":288,"tagName":"p"}]},{"val":[{"type":"text","content":"ADHD Portfolio, which consists of attention deficit hyperactivity disorder ("ADHD") products, net revenue was $9.1 million versus $15.4 million in Q3 fiscal 2025. The change in net revenue is primarily due to a transition of sales force prioritization toward EXXUA and the recent introduction of generic competition.","length":326,"tagName":"p"}]},{"val":[{"type":"text","content":"Pediatric Portfolio, which consists of a line of legacy products, net revenue was...